David B. Clarke

David B. Clarke

Auto-generated profile, based on publicly available information

David B. Clarke

Department of Surgery (Neurosurgery), Dalhousie University, Halifax, Canada

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2010 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
AOAmanda M. O’reilly
Amanda M. O’reilly
RCR. William Currie
R. William Currie
DCDavid B. Clarke
David B. Clarke

9 June 2021 in Journal of Community Health
Verified
Journal Article
Closed access
PDF file
NKNelofar Kureshi
Nelofar Kureshi
MEMete Erdogan
Mete Erdogan
GTGinette Thibault-Halman
Ginette Thibault-Halman
LFLynne Fenerty
Lynne Fenerty
RGRobert S. Green
Robert S. Green
DCDavid B. Clarke
David B. Clarke

16 September 2008 in Brain Research
Verified
Journal Article
Closed access
PNP.E.B. Nickerson
P.E.B. Nickerson
NSN. Da Silva
N. Da Silva
TMT. Myers
T. Myers
KSK. Stevens
K. Stevens
DCD.B. Clarke
D.B. Clarke

15 December 2023 in Science Advances
Verified
Journal Article
Open access
Mark A. MacLeanMark A. MacLean
Mark A. MacLean
JMJamil H. Muradov
Jamil H. Muradov
RGRyan Greene
Ryan Greene
GHGerben Van Hameren
Gerben Van Hameren
DCDavid B. Clarke
David B. Clarke
AFAlon Friedman
Alon Friedman
Cortical spreading depolarization (CSD) is a promising target for neuroprotective therapy in traumatic brain injury (TBI). We explored the effect of NMDA receptor antagonism on electrically triggered CSDs in healthy and brain-injured animals. Rats received either one moderate or four daily repetitive mild closed head impacts (rmTBI). Ninety-three animals underwent craniectomy with electrocorticographic (ECoG) and local blood flow monitoring. In brain-injured animals, ketamine or memantine inhibited CSDs in 44 to 88% and 50 to 67% of cases, respectively. Near-DC/AC-ECoG amplitude was reduced by 44 to 75% and 52 to 67%, and duration by 39 to 87% and 61 to 78%, respectively. Daily memantine significantly reduced spreading depression and oligemia following CSD. Animals (N= 31) were randomized to either memantine (10 mg/kg) or saline with daily neurobehavioral testing. Memantine-treated animals had higher neurological scores. We demonstrate that memantine improved neurovascular function following CSD in sham and brain-injured animals. Memantine also prevented neurological decline in a blinded, preclinical randomized rmTBI trial.

1 November 2007 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
PNPhilip E. B. Nickerson
Philip E. B. Nickerson
JEJason G. Emsley
Jason G. Emsley
TMTanya Myers
Tanya Myers
DCDavid B. Clarke
David B. Clarke
Purpose. Despite the identification of a small population of cells residing in the ciliary body (CB) of the adult mammalian eye that have the capacity to generate retina-like cells in vitro, their activity in vivo remains quiescent. The authors sought to identify whether the predictable and time-dependent death of retinal ganglion cells (RGCs) results in activation of progenitor-like cells within the CB. methods. RGC injury was induced by optic nerve axotomy in adult mice. Thymidine-analogue lineage tracing and immunocytochemistry were used to identify dividing cells and the phenotype of newly generated progeny. results. Two populations of nestin-expressing cells are present in the CB of the uninjured eye. One population resides in periendothelial cells of blood vessels, and a second resides in the ciliary epithelium. Axotomy increases proliferation in the CB, a response that begins before the onset of RGC death and continues during a time that corresponds with the peak in RGC death. In addition, a subpopulation of nestin-positive cells in the CB upregulates the homeodomain protein Chx10. Finally, recoverin, the expression of which is normally restricted to photoreceptors and bipolar cells of the retina, is upregulated in the CB in a manner that is independent of proliferation. conclusions. Together, these results suggest that progenitorlike cells of the CB respond to cues associated with the loss of a single retinal cell type and that a subpopulation of those cells may differentiate into a cell that bears phenotypic resemblance to those seen in the retina.

1 January 2016 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
SISyed Ali Imran
Syed Ali Imran
JTJitske Tiemensma
Jitske Tiemensma
SKStephanie M Kaiser
Stephanie M Kaiser
MVMichael Vallis
Michael Vallis
SDSteve Doucette
Steve Doucette
DCDavid B Clarke
David B Clarke
Objective:Acromegaly is frequently associated with altered facial appearance at the time of diagnosis. Furthermore, acromegaly is also associated with adverse psychological outcomes. We conducted a single-centre, cross-sectional study comparing patients with growth hormone vs non-functioning pituitary adenomas (NFA) to assess the association between morphometric changes and psychological outcomes and illness perception of patients with acromegaly.Methods:A seven-step scale was developed to grade morphometric changes based on facial photographs. In addition, all patients were asked to draw an image of their own body and an image of what they considered to be an average healthy body and complete seven psychological questionnaires. We recruited 55 consecutive patients in each of the two groups who had undergone surgery with or without radiation therapy (RT).Results:Our data showed that the clinician-rated morphometric scale was highly reliable in assessing facial changes, with 93/99 (Intraclass correlation coefficient (ICC)=0.95 (0.93–0.97)) graded as similar by independent raters. The mean (s.d.) grading for Acro and NFA patients on the clinician-rated morphometric scale were 3.5 (1.3) and 0.41 (0.35) respectively (P<0.0001). A higher clinician-rated morphometric score was also predictive of a poorer score on the drawing test.Conclusions:Our study demonstrates a correlation between physical changes associated with acromegaly and poor psychological outcomes, whereas no such correlation existed with modes of therapy, disease control status, RT, malignancy, initial or recent GH/IGF1 or secondary hormonal deficiency. Our data support the utility of the morphometric scale as a clinical tool for grading facial changes.